Elacestrant vs Imlunestrant
Same mechanism, same race: design-graded trial evidence for both assets, with the grading rationale shown. Grades describe the quality of the evidence, never the merits of either security.
HR+/HER2- Metastatic Breast Cancer
Shared mechanism: Estrogen receptor · full HR+/HER2- Metastatic Breast Cancer pipeline
Elacestrant
Marketed by Stemline Therapeutics, Inc. and partners
NCT03778931 · Phase 3 · completed
This was a large randomized trial comparing elacestrant with active standard-of-care treatment, but it was open-label rather than double-blind. The primary progression-free survival endpoints, assessed by blinded imaging review, were statistically significantly better with elacestrant in both ESR1-mutant and all participants, but the lack of participant and investigator blinding limits the strength of the evidence.
Next expected readout: November 2026 · NCT06691035 (registry estimate)
Reported efficacy
Progression-free Survival in ESR1-mut Participants (From Date of Randomization until Disease Progression or Death Due to Any Cause (up to 12 Months)); Progression-free Survival in All Participants (From Date of Randomization until Disease Progression or Death Due to Any Cause (up to 12 Months)): Progression-free Survival in ESR1-mut Participants (From Date of Randomization until Disease Progression or Death Due to Any Cause (up to 12 Months)): Elacestrant 3.78 months (95% CI 2.17 to 7.26) vs Standard of Care (SoC) 1.87 months (95% CI 1.87 to 2.14) (met)
Result source: NCT03778931
Imlunestrant · Inluriyo
Marketed by Eli Lilly
NCT04975308 · Phase 3 · active, not recruiting
EMBER-3 randomised 874 patients with ER-positive, HER2-negative advanced breast cancer in an open-label design, with three registered primary PFS comparisons. Imlunestrant beat standard endocrine therapy in patients with ESR1 mutations (HR 0.617, p=0.0008) but not in all patients (HR 0.867, p=0.1158), and the combination with abemaciclib beat imlunestrant alone (HR 0.569, p<0.0001). The result is mixed across the primaries and the open-label design keeps the grade at moderate.
Next expected readout: October 2028 · NCT07905001 (registry estimate)
Reported efficacy
Investigator-assessed Progression Free Survival (PFS) (Between Arm A and Arm B) (Randomization to the date of first documented progression of disease or death from any cause (up to 28 months)); Investigator-assessed PFS (Between Arm C and Arm A) (Randomization to the date of first documented progression of disease or death from any cause (up to 26 months)); Investigator-assessed PFS in the Estrogen Receptor 1 (ESR1)-Mutation Detected Population (Between Arm A and Arm B) (Randomization to the date of first documented progression of disease or death from any cause (up to 28 months)): Investigator-assessed PFS. ESR1-mutated population: imlunestrant 5.49 vs 3.84 months with standard endocrine therapy, HR 0.617 (95% CI 0.464 to 0.821), p=0.0008. All patients: 5.55 vs 5.52 months, HR 0.867 (95% CI 0.724 to 1.039), p=0.1158 (not significant). Imlunestrant plus abemaciclib vs imlunestrant: 9.36 vs 5.49 months, HR 0.569 (95% CI 0.441 to 0.733), p<0.0001 (mixed)
Result source: NCT04975308
Results for HR+/HER2- Metastatic Breast Cancer
Values come from each drug's own ClinicalTrials.gov study. They are from separate trials and patient populations, not a head-to-head comparison. Each result identifies its source trial, phase, arm and timepoint; limitations that apply to a whole cell are marked with a letter and listed once beneath the table. The comparison is deepest for later-stage drugs (phase 3 or approved), which usually have posted results to draw on; early-stage drugs often have none yet.
| Key endpoint | Elacestrant | Imlunestrant |
|---|---|---|
| PFS, median | 3.8 vs 1.9vs Standard of Care (SoC)NCT037789311 other result
| 5.5 vs 5.5vs Investigator's Choice of Endocrine TherapyNCT049753087 other results
|
| OS, median | —Trial running · NCT06382948 | —Trial running · NCT04975308 |
| ORR | —Trial running · NCT06382948 | 10.3% vs 6.4%vs Investigator's Choice of Endocrine TherapyNCT049753083 other results
|
| Clinical benefit rate | —Trial running · NCT06382948 | 46.8% vs 45.5%vs Investigator's Choice of Endocrine TherapyNCT049753083 other results
|
PFS, median
- Elacestrant
- 3.8 vs 1.9vs Standard of Care (SoC)NCT03778931
1 other result
- 2.8 vs 1.9 NCT03778931
- Imlunestrant
- 5.5 vs 5.5vs Investigator's Choice of Endocrine TherapyNCT04975308
7 other results
- 5.5 vs 3.8 NCT04975308
- 9.4 NCT04975308
- 5.5 NCT04975308
- 9.2 vs 7.4 NCT04975308
- 7.4 vs 5.5 NCT04975308
- 14.5 NCT04975308
- 9.2 NCT04975308
OS, median
- Elacestrant
- —Trial running · NCT06382948
- Imlunestrant
- —Trial running · NCT04975308
ORR
- Elacestrant
- —Trial running · NCT06382948
- Imlunestrant
- 10.3% vs 6.4%vs Investigator's Choice of Endocrine TherapyNCT04975308
3 other results
- 11.6% vs 5.9% NCT04975308
- 21.1% NCT04975308
- 9.4% NCT04975308
Clinical benefit rate
- Elacestrant
- —Trial running · NCT06382948
- Imlunestrant
- 46.8% vs 45.5%vs Investigator's Choice of Endocrine TherapyNCT04975308
3 other results
- 46.4% vs 36.4% NCT04975308
- 62.9% NCT04975308
- 44.1% NCT04975308
- Each cell is from that drug's own trial. Trials differ in population, design and timepoint; this is not a head-to-head comparison.
- An empty cell names why: Not posted (a completed Phase 3 here has no posted results yet), Trial running, Pending review (we hold the result and are checking it) or Not reported.
Only safety results can currently be compared in this indication. Reviewed efficacy summaries, where available, are listed separately.
safety
Coverage. Elacestrant: 3 of 4 rows · Imlunestrant: 4 of 4 rows. A dash means no reviewed, structured value is available for that endpoint in this indication.
| Reported metric | Elacestrant | Imlunestrant |
|---|---|---|
| Dropout rate | 36.4% NCT03778931 · Phase 3 · monotherapy · Breast Cancer, HR+/HER2- Metastatic Breast Cancer · phase 3 | 25.7%Arm A: Imlunestrant NCT04975308 · Phase 3 · monotherapy · Breast Cancer, HR+/HER2- Metastatic Breast Cancer · phase 3 show 1 more result45.1%Arm C: Imlunestrant + Abemaciclib NCT04975308 · Phase 3 · combination · Breast Cancer, HR+/HER2- Metastatic Breast Cancer · phase 3 |
| Discontinued due to AEs | — NCT03778931 · Phase 3 · monotherapy · Breast Cancer, HR+/HER2- Metastatic Breast Cancer · phase 3 | 3%Arm A: Imlunestrant NCT04975308 · Phase 3 · monotherapy · Breast Cancer, HR+/HER2- Metastatic Breast Cancer · phase 3 show 1 more result5.6%Arm C: Imlunestrant + Abemaciclib NCT04975308 · Phase 3 · combination · Breast Cancer, HR+/HER2- Metastatic Breast Cancer · phase 3 |
| Serious AEs | 12.2% NCT03778931 · Phase 3 · monotherapy · Breast Cancer, HR+/HER2- Metastatic Breast Cancer · phase 3 | 14.1%Arm A: Imlunestrant NCT04975308 · Phase 3 · monotherapy · Breast Cancer, HR+/HER2- Metastatic Breast Cancer · phase 3 show 1 more result20.2%Arm C: Imlunestrant + Abemaciclib NCT04975308 · Phase 3 · combination · Breast Cancer, HR+/HER2- Metastatic Breast Cancer · phase 3 |
| Most frequent reported AEs | nausea 35% fatigue 19% vomiting 19% NCT03778931 · Phase 3 · monotherapy · Breast Cancer, HR+/HER2- Metastatic Breast Cancer · phase 3 | diarrhoea 21.7% nausea 18% arthralgia 15.3% NCT04975308 · Phase 3 · monotherapy · Breast Cancer, HR+/HER2- Metastatic Breast Cancer · phase 3 show 1 more resultdiarrhoea 86.5% nausea 50% anaemia 43.8% NCT04975308 · Phase 3 · combination · Breast Cancer, HR+/HER2- Metastatic Breast Cancer · phase 3 |
Reported by one asset only
Endpoints only one of the selected assets measured, so there is nothing to compare them against.
Elacestrant
show 1 more result
Imlunestrant
show 3 more results
show 1 more result
show 1 more result
show 1 more result
show 1 more result
show 1 more result
show 1 more result
Breast Cancer
Shared mechanism: Estrogen receptor · full Breast Cancer pipeline
Elacestrant
Marketed by Stemline Therapeutics, Inc. and partners
NCT03778931 · Phase 3 · completed
This was a large randomized trial comparing elacestrant with active standard-of-care treatment, but it was open-label rather than double-blind. The primary progression-free survival endpoints, assessed by blinded imaging review, were statistically significantly better with elacestrant in both ESR1-mutant and all participants, but the lack of participant and investigator blinding limits the strength of the evidence.
Next expected readout: November 2026 · NCT06691035 (registry estimate)
Reported efficacy
Progression-free Survival in ESR1-mut Participants (From Date of Randomization until Disease Progression or Death Due to Any Cause (up to 12 Months)); Progression-free Survival in All Participants (From Date of Randomization until Disease Progression or Death Due to Any Cause (up to 12 Months)): Progression-free Survival in ESR1-mut Participants (From Date of Randomization until Disease Progression or Death Due to Any Cause (up to 12 Months)): Elacestrant 3.78 months (95% CI 2.17 to 7.26) vs Standard of Care (SoC) 1.87 months (95% CI 1.87 to 2.14) (met)
Result source: NCT03778931
Imlunestrant · Inluriyo
Marketed by Eli Lilly
NCT04975308 · Phase 3 · active, not recruiting
EMBER-3 randomised 874 patients with ER-positive, HER2-negative advanced breast cancer in an open-label design, with three registered primary PFS comparisons. Imlunestrant beat standard endocrine therapy in patients with ESR1 mutations (HR 0.617, p=0.0008) but not in all patients (HR 0.867, p=0.1158), and the combination with abemaciclib beat imlunestrant alone (HR 0.569, p<0.0001). The result is mixed across the primaries and the open-label design keeps the grade at moderate.
Next expected readout: October 2027 · NCT05514054 (registry estimate)
Reported efficacy
Investigator-assessed Progression Free Survival (PFS) (Between Arm A and Arm B) (Randomization to the date of first documented progression of disease or death from any cause (up to 28 months)); Investigator-assessed PFS (Between Arm C and Arm A) (Randomization to the date of first documented progression of disease or death from any cause (up to 26 months)); Investigator-assessed PFS in the Estrogen Receptor 1 (ESR1)-Mutation Detected Population (Between Arm A and Arm B) (Randomization to the date of first documented progression of disease or death from any cause (up to 28 months)): Investigator-assessed PFS. ESR1-mutated population: imlunestrant 5.49 vs 3.84 months with standard endocrine therapy, HR 0.617 (95% CI 0.464 to 0.821), p=0.0008. All patients: 5.55 vs 5.52 months, HR 0.867 (95% CI 0.724 to 1.039), p=0.1158 (not significant). Imlunestrant plus abemaciclib vs imlunestrant: 9.36 vs 5.49 months, HR 0.569 (95% CI 0.441 to 0.733), p<0.0001 (mixed)
Result source: NCT04975308
Results for Breast Cancer
Values come from each drug's own ClinicalTrials.gov study. They are from separate trials and patient populations, not a head-to-head comparison. Each result identifies its source trial, phase, arm and timepoint; limitations that apply to a whole cell are marked with a letter and listed once beneath the table. The comparison is deepest for later-stage drugs (phase 3 or approved), which usually have posted results to draw on; early-stage drugs often have none yet.
Coverage. Elacestrant: 4 of 5 rows · Imlunestrant: 5 of 5 rows. A dash means no reviewed, structured value is available for that endpoint in this indication.
| Reported metric | Elacestrant | Imlunestrant |
|---|---|---|
| PFS time to event · months | 3.78 vs 1.87 Standard of Care (SoC) monthsa,b NCT03778931 · Phase 3 · monotherapy · Breast Cancer, HR+/HER2- Metastatic Breast Cancer · phase 3 show 1 more dose2.79 vs 1.91 Standard of Care (SoC) months NCT03778931 · Phase 3 · monotherapy · Breast Cancer, HR+/HER2- Metastatic Breast Cancer · phase 3 | 5.55 vs 5.52 Investigator's Choice of Endocrine Therapy monthsa,b NCT04975308 · Phase 3 · monotherapy · Breast Cancer, HR+/HER2- Metastatic Breast Cancer · phase 3 show 3 more doses5.49 vs 3.84 Investigator's Choice of Endocrine Therapy months NCT04975308 · Phase 3 · monotherapy · Breast Cancer, HR+/HER2- Metastatic Breast Cancer · phase 3 9.23 vs 7.36 Investigator's Choice of Endocrine Therapy months NCT04975308 · Phase 3 · monotherapy · Breast Cancer, HR+/HER2- Metastatic Breast Cancer · phase 3 7.43 vs 5.49 Investigator's Choice of Endocrine Therapy months NCT04975308 · Phase 3 · monotherapy · Breast Cancer, HR+/HER2- Metastatic Breast Cancer · phase 3 |
| Dropout rate | 36.4% NCT03778931 · Phase 3 · monotherapy · Breast Cancer, HR+/HER2- Metastatic Breast Cancer · phase 3 | 25.7%Arm A: Imlunestrant NCT04975308 · Phase 3 · monotherapy · Breast Cancer, HR+/HER2- Metastatic Breast Cancer · phase 3 show 1 more result45.1%Arm C: Imlunestrant + Abemaciclib NCT04975308 · Phase 3 · combination · Breast Cancer, HR+/HER2- Metastatic Breast Cancer · phase 3 |
| Discontinued due to AEs | — NCT03778931 · Phase 3 · monotherapy · Breast Cancer, HR+/HER2- Metastatic Breast Cancer · phase 3 | 3%Arm A: Imlunestrant NCT04975308 · Phase 3 · monotherapy · Breast Cancer, HR+/HER2- Metastatic Breast Cancer · phase 3 show 1 more result5.6%Arm C: Imlunestrant + Abemaciclib NCT04975308 · Phase 3 · combination · Breast Cancer, HR+/HER2- Metastatic Breast Cancer · phase 3 |
| Serious AEs | 12.2% NCT03778931 · Phase 3 · monotherapy · Breast Cancer, HR+/HER2- Metastatic Breast Cancer · phase 3 | 14.1%Arm A: Imlunestrant NCT04975308 · Phase 3 · monotherapy · Breast Cancer, HR+/HER2- Metastatic Breast Cancer · phase 3 show 1 more result20.2%Arm C: Imlunestrant + Abemaciclib NCT04975308 · Phase 3 · combination · Breast Cancer, HR+/HER2- Metastatic Breast Cancer · phase 3 |
| Most frequent reported AEs | nausea 35% fatigue 19% vomiting 19% NCT03778931 · Phase 3 · monotherapy · Breast Cancer, HR+/HER2- Metastatic Breast Cancer · phase 3 | diarrhoea 21.7% nausea 18% arthralgia 15.3% NCT04975308 · Phase 3 · monotherapy · Breast Cancer, HR+/HER2- Metastatic Breast Cancer · phase 3 show 1 more resultdiarrhoea 86.5% nausea 50% anaemia 43.8% NCT04975308 · Phase 3 · combination · Breast Cancer, HR+/HER2- Metastatic Breast Cancer · phase 3 |
Notes
- aThis study reports multiple eligible drug arms; no representative arm has been reviewed.
- bThe assessment timepoint is not available for both results.
Reported by one asset only
Endpoints only one of the selected assets measured, so there is nothing to compare them against.
Elacestrant
show 1 more result
Imlunestrant
show 3 more results
show 1 more result
show 1 more result
show 1 more result
show 1 more result
show 1 more result
show 1 more result
The full competitive landscape for each asset (every same-race competitor with aligned evidence, sortable) is on the asset pages: Elacestrant's landscape · Imlunestrant's landscape